| Literature DB >> 32791136 |
Ali Akbar Samadani1, Arman Keymoradzdeh2, Shima Shams2, Armin Soleymanpour2, Seyedeh Elham Norollahi3, Sogand Vahidi3, Ali Rashidy-Pour4, Ali Ashraf3, Ebrahim Mirzajani5, Korosh Khanaki6, Morteza Rahbar Taramsari7, Sedigheh Samimian3, Akram Najafzadeh8.
Abstract
Cancer stem cells (CSCs) are responsible for carcinogenesis and tumorigenesis and are involved in drug and radiation resistance, metastasis, tumor relapse and initiation. Remarkably, they have other abilities such as inheritance of self-renewal and de-differentiation. Hence, targeting CSCs is considered a potential anti-cancer therapeutic strategy. Recent advances in the identification of biomarkers to recognize CSCs and the development of new techniques to evaluate tumorigenic and carcinogenic roles of CSCs are instrumental to this approach. Elucidation of signaling pathways that regulate CSCs colony progression and drug resistance are critical in establishing effective targeted therapies. CSCs play a central key role in immunomodulation, immune evasion and effector immunity, which alters immune system balancing. These include mTOR, SHH, NOTCH and Wnt/β-catering in cancer progression. In this review article, we discuss the importance of these CSCs pathways in cancer therapy.Entities:
Keywords: Cancer stem cells; Signaling pathways; Therapy
Mesh:
Year: 2020 PMID: 32791136 DOI: 10.1016/j.cca.2020.08.016
Source DB: PubMed Journal: Clin Chim Acta ISSN: 0009-8981 Impact factor: 3.786